Nasdaq: VRDN

Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker VRDN. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
VRDN
Exchange
Nasdaq
SEC CIK
1590750
Official filings
SEC EDGAR

Research VRDN

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Viridian Therapeutics, Inc.'s stock ticker?

Viridian Therapeutics, Inc. trades under the ticker symbol VRDN on Nasdaq. Its SEC Central Index Key (CIK) is 1590750.

Where can I read Viridian Therapeutics, Inc.'s SEC filings?

The VRDN SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Viridian Therapeutics, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze VRDN's financial statements?

The VRDN Financials page shows Viridian Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does VRDN compare with its peers and the market?

The VRDN Peer Comparison page lines Viridian Therapeutics, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.